Get the app
Marc de Garidel
Chief executive officer of Abivax, leading development of obefazimod and discussing the company's clinical data, regulatory roadmap, and 2026 plans.
Best podcasts with Marc de Garidel
Ranked by the Snipd community
Jan 12, 2026
• 11min
SF Healthcare Week: Abivax CEO Marc de Garidel reflects on a breakout 2025 for obefazimod and key data that will read out this year
chevron_right
In this engaging discussion, Marc de Garidel, CEO of Abivax, shares insights into the promising future of obefazimod, highlighting key 2025 data and plans for 2026. He emphasizes the importance of upcoming clinical data for ulcerative colitis and Crohn's disease. Marc also addresses market pressures and M&A speculation while reassuring listeners about the safety profiles observed in trials. He describes obefazimod's unique mechanism as an immunostabilizer, offering hope for patients and optimism for forthcoming results related to fibrosis and TH17 effects.
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
Get the app
